ClinicalTrials.gg
TerminatedNCT00946985Updated Sep 10, 2012Results posted

28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

A Phase 4 interventional study of paliperidone palmitate and oral risperidone in Schizophrenia, sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC. Terminated at 76 sites in 12 countries. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2012-09-10.

Sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Prevention

Why this study was terminated
The recruitment rate for the study was inadequate to achieve its enrollment goals.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
163
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
60th of 115
163 · median 178
Started
2009
with 10 others
Phase 4
42 of 115
5 open now
Registered
47th of 115
by date

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 60th largest by enrollment, is one of 11 that started in 2009, is one of 42 in phase 4, and was the 47th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The study will assess the use of paliperidone palmitate compared with oral risperidone in delaying time to relapse in patients recently diagnosed with schizophrenia who are at high risk of relapse.

Read the detailed description

This is a Prospective, Randomized, Active-controlled, Rater-blinded Study to to assess the efficacy of paliperidone palmitate compared with oral risperidone in delaying time to relapse in patients recently diagnosed with schizophrenia who are at high risk of relapse. Recently diagnosed is defined as first diagnosis of any psychotic disorder within 5 years prior to screening. High risk of relapse is defined as having documented occurrence of 3 periods of breakthrough symptoms that required a change in patient care per the investigator's judgment (e.g., increase in dose, addition of a new drug, increase in the level of psychiatric care, notable increases in the frequency or intensity of patient contact required to maintain outpatient status, psychiatric hospitalization, etc.) within the previous 24 months, including 1 such period within the previous 6 months. Safety evaluations will include Adverse Event (AE) reporting, hematology and clinical chemistry laboratory tests, vital signs, electrocardiogram (ECG), and evaluations of suicidality and sexual functioning. Patients will receive either paliperidone palmitate 50, 75, 100, or 150 mg eq. monthly by injection for two years or oral risperidone 2, 4, 6, or 8 mg tabs once daily for two years.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Risperidone
  • Risperdal
  • Paliperidone Palmitate
  • Invega Sustenna
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be, in the opinion of the investigator, able to understand the form approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC), as appropriate
  • All patients must sign the study informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
  • Must have a current diagnosis of schizophrenia
  • must have had 3 periods of breakthrough symptoms that required a change in patient care as determined by the investigator (e.g. increase in dose, addition of a new drug, hospitalization, increase in the level of psychiatric care, notable increases in the frequency or intensity of patient contact required to maintain outpatient status, etc.) within the previous 24 months, including 1 such period within the previous 6 months
  • Women must be , surgically sterile, or otherwise be incapable of pregnancy, abstinent, or if sexually active, be practicing a highly effective method of before entry, and must agree to continue to use the same method of contraception throughout the study
  • Women of must have a negative urine pregnancy test at screening
  • Patients must be cooperative and reliable, agree to receive regular injections, and be willing/able to adhere to the prohibitions and restrictions specified in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Patients who are unable to provide their own consent or are involuntarily committed to psychiatric hospitalization
  • Have attempted suicide within 12 months before screening or are at imminent risk of suicide or violent behavior
  • Have a positive urine drug screen test for barbiturates, cocaine, amphetamines, or opiates at screening
  • Patients who are in their first episode of psychosis
  • Patients currently meeting criteria for any other Axis I diagnosis except substance abuse or an Axis II diagnosis of Mental Retardation or Borderline Personality Disorder
  • Meet the Diagnostic and Statistical Manual of Mental Health Disorders fourth edition () definition of substance dependence (except for nicotine and caffeine dependence) within 6-months prior to entry
  • Patients with known allergies, (anaphylaxis-type reaction), or intolerance to paliperidone palmitate, risperidone, Risperdal®, Risperdal® Consta®, or INVEGA® or its
  • Patients who received Long Acting Therapy (LAT) treatment within 2 injection cycles prior to screening
  • Women who are pregnant or breast-feeding, or planning to become pregnant.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    001

    paliperidone palmitate 50 75 100 or 150 mg eq. monthly injection for 2 years

    Drug: paliperidone palmitate

  • Active comparator
    002

    oral risperidone 2 4 6 or 8 mg tabs once daily for two years

    Drug: oral risperidone

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Relapse During Relapse Prevention Phase

    Time to relapse during the relapse prevention phase was the primary efficacy variable of the study. Each case of potential relapse event were to be reviewed in a blinded fasion by an independent Relapse Monitoring Board, comprised of experts in the diagnostic, clinical and therapeutic management of schizophrenia.

    Time frame: 24 months

07

Results

Posted Jul 16, 2012
Limitations and caveats
No efficacy analysis was performed due to early termination of the study (only 2 patients were randomized at the time of study termination).

Participant flow

This trial was intended to recruit patients from multiple sites in North America, Europe, and Asia.

Stabilization Phase (25 Weeks)
Participant flow — Stabilization Phase (25 Weeks)
MilestonePaliperidone Palmitate
Started162
Completed2
Not completed160
Withdrew: Adverse event4
Withdrew: Lack of efficacy3
Withdrew: Lost to follow-up5
Withdrew: Withdrawal by subject4
Withdrew: Study closed by sponsor139
Withdrew: Failed to meet stability criteria2
Withdrew: Prohibited medication during study1
Withdrew: Patient moved away2
Relapse Prevention Phase (24 Months)
Participant flow — Relapse Prevention Phase (24 Months)
MilestonePaliperidone Palmitate
Started2
Completed0
Not completed2
Withdrew: Study closed by sponsor2

Outcome measures

PrimaryTime to Relapse During Relapse Prevention Phase

Time to relapse during the relapse prevention phase was the primary efficacy variable of the study. Each case of potential relapse event were to be reviewed in a blinded fasion by an independent Relapse Monitoring Board, comprised of experts in the diagnostic, clinical and therapeutic management of schizophrenia.

Time frame:
24 months

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paliperidone Palmitate—6/162 (3.7%)50/162 (30.9%)
Most frequent serious events
Most frequent serious events
EventPaliperidone Palmitate
SchizophreniaPsychiatric disorders4/162
AggressionPsychiatric disorders1/162
DepressionPsychiatric disorders1/162
Self Injurious BehaviourPsychiatric disorders1/162
Hand FractureInjury, poisoning and procedural complications1/162
Most frequent other events
Most frequent other events
EventPaliperidone Palmitate
InsomniaPsychiatric disorders10/162
Injection Site PainGeneral disorders10/162
AgitationPsychiatric disorders8/162
AnxietyPsychiatric disorders8/162
HeadacheNervous system disorders8/162
TremorNervous system disorders8/162
Weight IncreasedInvestigations8/162
AkathisiaNervous system disorders5/162
Pain in ExtremityMusculoskeletal and connective tissue disorders5/162
RestlessnessPsychiatric disorders4/162

Baseline characteristics

Age Continuous
Age Continuous(years)Paliperidone Palmitate
Mean27 ± 4.55
Age, Customized
Age, Customized(participants)Paliperidone Palmitate
18-23 years46
24-29 years62
30-35 years54
Sex: Female, Male
Sex: Female, Male(Participants)Paliperidone Palmitate
Female54
Male108
Positive and Negative Syndrome Scale (PANSS) Total Score
Positive and Negative Syndrome Scale (PANSS) Total Score(units on a scale)Paliperidone Palmitate
Mean85.9 ± 13.65
Clinical Global Impression of Severity (CGI-S)
Clinical Global Impression of Severity (CGI-S)(units on a scale)Paliperidone Palmitate
Mean4.4 ± 0.56
Age at First Diagnosis of Schizophrenia
Age at First Diagnosis of Schizophrenia(years)Paliperidone Palmitate
Mean24.1 ± 4.61
Current Schizophrenia Diagnosis
Current Schizophrenia Diagnosis(participants)Paliperidone Palmitate
Paranoid (295.30)142
Disorganized (295.10)6
Undifferentiated (295.90)13
Residual (295.60)1
08

Study locations

76 sites
  • Little Rock, Arkansas, United States
  • Garden Grove, California, United States
  • San Diego, California, United States
  • Washington, District of Columbia, United States
  • Kissimmee, Florida, United States
  • Tampa, Florida, United States
  • Chicago, Illinois, United States
  • Hoffman Estates, Illinois, United States
  • Kingsport, Indiana, United States
  • Lake Charles, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Pittsfield, Massachusetts, United States
  • Minneapolis, Minnesota, United States
  • Flowood, Mississippi, United States
  • Creve Coeur, Missouri, United States
  • Saint Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Brooklyn, New York, United States
  • Middleburg Heights, Ohio, United States
  • Arlington, Texas, United States
  • Austin, Texas, United States
  • Irving, Texas, United States
  • Portsmount, Virginia, United States
  • Curitiba, Brazil
  • Salvador, Brazil
  • Sao Paulo, Brazil
  • Kazanlak, Bulgaria
  • Pleven, Bulgaria
  • Radnevo N/A, Bulgaria
  • Calgary, Alberta, Canada
  • Halifax, Nova Scotia, Canada
  • Sudbury, Ontario, Canada
  • Montreal, Quebec, Canada
  • Quebec, Canada
  • Baoding, China
  • Beijing, China
  • Changsha, China
  • Guangzhou, China
  • Kunming, China
  • Shanghai, China
  • Wuhan, China
  • Xi'An, China
  • Bogota, Colombia
  • Kutná Hora 1, Czech Republic
  • Olomouc 9, Czech Republic
  • Praha 10, Czech Republic
  • Praha 8, Czech Republic
  • Praha 9, Czech Republic
  • Strakonice 1, Czech Republic
  • Ahmedabad, India
  • Aurangabad, India
  • Calicut, India
  • Hyderabad, India
  • Jaipur, India
  • Lucknow Gpo, India
  • Mangalore, India
  • Pune, India
  • Varanasi, India
  • Chonju, Korea, Republic of
  • Gwangju, Korea, Republic of
  • Gyeonggi-Do, Korea, Republic of
  • Seoul, Korea, Republic of
  • Johor Bahru, Malaysia
  • Kuala Lumpur, Malaysia
  • Moscow, Russian Federation
  • Nizny Novgorod, Russian Federation
  • Samara N/A, Russian Federation
  • St Petersburg N/A, Russian Federation
  • St Petersburg, Russian Federation
  • St-Petersburg, Russian Federation
  • Yaroslavl N/A, Russian Federation
  • Kharkov, Ukraine
  • Kherson, Ukraine
  • Kiev, Ukraine
  • Odessa, Ukraine
  • Simferopol, Ukraine
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2009
First posted
Jul 27, 2009
Start
Jun 2009
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Jul 16, 2012
Last update
Sep 10, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00946985
Responsible party
Sponsor
First posted
Jul 27, 2009
Start date
Jun 2009
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Jul 16, 2012
Last update
Sep 10, 2012

Study contacts

Ortho-McNeil Janssen Scientific Affairs, LLC Clinical Trial
study director · Ortho-McNeil Janssen Scientific Affairs, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion